Alpine Immune Sciences, Inc. (ALPN) operates as a clinical-stage immunotherapy company.

It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases.

The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.

Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Please note, this stock reported earnings on Monday, March 18th.

Alpine Immune Sciences reported earnings of $0.15 per share on revenue of $30.85 million for the fourth quarter ended December 2023. The consensus estimate was a loss of $0.32 per share on revenue of $9.10 million. The company beat consensus estimates by 146.88% while revenue grew 1,011.42% on a year-over-year basis.

After a strong earnings report, shares should head higher.